Broadcasting from ESC 2024 - Siddharth Patel, MD, MPH: Abelacimab Could Help Reduce Procedure-Related Bleeding
New data from the AZALEA-TIMI 71 trial is shedding further light on the potential benefits of factor XI inhibition with abelacimab.
Presented at the European Society of Cardiology (ESC) Congress 2024, the analysis focused on periprocedural and procedural-related bleeding events, with results demonstrating use of abelacimab was associated with a reduced rate of major and clinically relevant nonmajor bleeding events.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
